Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
作者
Surya Prakash Bhatt,Klaus Friedrich Rabe,Nicola Alexander Hanania,Claus Franz Vogelmeier,Jeremy Cole,Mona Bafadhel,Stephanie A. Christenson,Alberto A. Papi,Dave Singh,Elizabeth Laws,Leda Mannent,Eric R. Mortensen,Jennifer M. Maloney,Xin Lu,Déborah Bauer,Ashish Bansal,Lacey B. Robinson,Raolat M. Abdulai
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2023-09-09卷期号:: PA1308-PA1308
标识
DOI:10.1183/13993003.congress-2023.pa1308
摘要
Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4 and IL-13, key/central drivers of Type 2 (T2) inflammation. Objective: Determine efficacy/safety in patients with moderate-to-severe COPD with T2 inflammation. Methods: BOREAS (NCT03930732) was a 52-week (wk), phase 3, randomized, double-blind, placebo (PBO)-controlled trial of efficacy/safety of biweekly DPL 300mg in COPD pts with blood eosinophils ≥300cells/µL at screening, on triple therapy (an inhaled corticosteroid [ICS], long-acting β2-agonists [LABA], and long-acting muscarinic antagonists [LAMA]; or LABA/LAMA if ICS was contraindicated) without asthma diagnosis/history. Primary endpoint: annualized rate of moderate-severe exacerbations. Secondary/other endpoints: change from baseline (BL) in pre-bronchodilator FEV1 at wk 12 and wk 52; cumulative exacerbations over time; safety. Results: 939 participants were randomized to PBO (N=471) or DPL (N=468). DPL reduced exacerbation rates by 30% vs PBO (p=0.0005). DPL significantly increased pre-BD FEV1 at wk 12 (LSM difference vs PBO: 83mL, p<0.0001); sustained through wk 52 (83mL, p=0.0003). This trended towards reduced exacerbation-associated annualized total SCS treatment duration for DPL (13.57 days [SD 13.17] vs for PBO (19.09 days [SD 20.65]). Safety similar in DPL and PBO groups; TEAEs balanced. Conclusions: DPL significantly improved moderate-severe exacerbations, lung function, quality of life, and symptoms in COPD patients with T2 inflammation. The use of SCS days required for the treatment of AECOPD trended lower with DPL.